TheraVet announces the commercial launch of BIOCERA-VET
April 01, 2021
TheraVet S.A., a pioneering company in the management of osteoarticular diseases in pets, announced today the commercial launch of BIOCERA-VET, its new generation bone substitute for the treatment of bone surgeries in small companions. BIOCERA-VET will initially be commercialized on the Belgian orthopedic market and will quickly be extended to France and the Netherlands. Due to the growing importance of pets and of their quality of life for their owners, animal health is becoming more and more a social and medical issue ...
PREVIOUS PRESS RELEASES
Positive results of a single intra-articular injection of VISCO-VET in canine osteoarthritis
Positive results in canine cranial cruciate ligament deficiency
TheraVet raises 4 M€ to accelerate the development of its two veterinary products
March 04, 2021
TheraVet S.A., a pioneering company in the management of osteoarticular diseases in pets, announced today positive results for its study evaluating VISCO-VET, its injectable visco-regenerative gel, in the prevention and treatment of osteoarthritis in a canine model of the disease. Osteoarthritis (OA) is a progressive degenerative joint disease characterized by a loss of joint cartilage...
January 26, 2021
TheraVet S.A., a pioneering company in the osteoarticular diseases of the companion animals, announced today the positive results of VISCO-VET, its injectable visco-regenerating gel, in the prevention of cranial cruciate ligament (CCL) deficiency in canine model of cranial cruciate ligament deficiency. CCL deficiency is one of the most important cause of stifle (knee) instability and lameness...
December 10, 2020
TheraVet S.A., the specialist of the osteo-articular diseases in small companion animals, announces today that it will raise by the end of 2020 €4 million of additional funding for the development of its innovative veterinary product lines. This funding consists of a capital increase of €1.9 million realized with TheraVet's historical shareholders...
TheraVet launches a prospective multicentric clinical trial in canine osteosarcoma
TheraVet completes first regulatory milestones for the US registration (NADA) of VISCO-VET in canine osteoarthritis
TheraVet starts its US operations in its Texas-based subsidiary